RxDoctor Payments DataLook up a doctor →

Kylie Money, PA

Physician Assistant · Ogden, UTNPI 1871058131

Payments from drug & device makers

$24,516in general payments, 2019–2025

Across 763 payments — averaging $32.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$5K
  • Eli Lilly$2K
  • G1 Therapeutics, Inc.$1K
  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Daiichi Sankyo Inc.$1K
  • plus $12K from 54 others
$4,327in research payments, 2019–2025

Across 31 payments — averaging $139.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$3K
  • AbbVie$2K

What the payments were for

  • Consulting fees$2,47510%
  • Speaking & faculty fees$1,0004%
  • Travel & lodging$1,0284%
  • Food & beverage$15,99465%
  • Education$1,5206%
  • Other$2,49810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis111$4,635
Eli Lilly1$2,475
G1 Therapeutics, Inc.4$1,365
AstraZeneca(2 entities)45$1,283
Johnson & Johnson43$1,149
Daiichi Sankyo Inc.40$1,047
Genentech USA, Inc.29$830
Seagen Inc.16$660
Sanofi19$658
Incyte Corporation17$625
Astellas Pharma US Inc18$622
Merck29$599
Lilly USA, LLC24$545
AbbVie28$482
Regeneron Healthcare Solutions, Inc.16$459
Bristol Myers Squibb22$435
Pfizer40$409
Takeda Pharmaceuticals U.S.A., Inc.15$351
GSK14$338
Beigene USA, Inc.10$328
EMD Serono, Inc.16$308
Gilead(2 entities)10$289
Eisai Inc.14$280
E.r. Squibb & Sons, L.L.C.12$273
Tersera Therapeutics LLC12$261
Genmab U.S., Inc.10$251
Beone Medicines USA, Inc.2$176
Amneal Pharmaceuticals LLC8$175
Myriad Genetic Laboratories, Inc.4$174
Boehringer Ingelheim6$166
Sobi, Inc3$144
Dendreon Pharmaceuticals LLC2$129
Array Biopharma Inc7$118
Myriad Women's Health, Inc.2$112
Servier Pharmaceuticals LLC5$112
Bayer6$109
Pharmacyclics LLC, An Abbvie Company5$108
Mylan Institutional Inc.4$106
Organon8$101
Pharmacosmos Therapeutics Inc.5$99
Jazz Pharmaceuticals Inc.6$99
Sanofi-aventis U.S. LLC1$99
Deciphera Pharmaceuticals Inc.5$93
TG Therapeutics, Inc.1$87
Amgen3$85
Sumitomo Pharma America, Inc.4$81
Pharmaessentia USA Corporation4$75
Blueprint Medicines Corporation3$71
Coherus Oncology, Inc.3$65
Geron Corporation3$64
Karyopharm Therapeutics Inc.3$63
Ipsen Biopharmaceuticals, Inc3$53
Puma Biotechnology, Inc.3$52
Immunocore Limited2$50
Agios Pharmaceuticals, Inc.2$45
EUSA Pharma (US) LLC2$43
Recordati_rare_diseases_inc.2$42
Exelixis Inc.2$40
Azurity Pharmaceuticals, Inc.2$40
Springworks Therapeutics, Inc.2$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,516 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$1,253,787
Medicare patients
387
Services billed
75,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate12$300,877
EliquisApixaban36$30,394
XareltoRivaroxaban23$15,217
Enoxaparin Sodium11$6,274
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen53$1,988
Fentanyl19$1,737
Tamoxifen Citrate27$1,131
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$812
Hydroxyurea20$694
Letrozole26$596
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine14$582
Ondansetron Hcl15$550
Gabapentin23$430
Omeprazole25$348
Levothyroxine Sodium42$337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$40$300,87712 claims
PfizerEliquis$409$30,39436 claims
Johnson & JohnsonXarelto$1,149$15,21723 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$175$33742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →